Atea Pharmaceuticals (AVIR) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 66.3% versus a gain of 7.1%. Over five years, CAPR leads with a +102.3% price change compared with -86.9% for AVIR. Capricor Therapeutics is the larger company by market cap ($455.2 million vs $413.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | CAPR |
|---|---|---|
| Share price | $5.15 | $7.83 |
| Market cap | $413.05M | $455.23M |
| 1-day change | -0.10% | -2.25% |
| YTD return | +44.40% | -72.25% |
| 1-year return | +66.29% | +7.09% |
| 5-year return | -86.88% | +102.27% |
| EPS (TTM) | $-2.09 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $40.37 |
| 52-week low | $2.87 | $2.96 |
| Distance from 52-week high | -20.16% | -80.60% |
| Analyst consensus | none | buy |
| Avg. price target upside | +82.91% | +244.83% |
| Average volume | 298.98K | 6.87M |
| Shares outstanding | 80.20M | 58.14M |
| Employees | 55 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed CAPR by 59.2 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
AVIR vs CAPR FAQ
Which is bigger, Atea Pharmaceuticals or Capricor Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $455.23M compared with $413.05M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or CAPR?
AVIR returned +66.29% over the past 12 months, compared with +7.09% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Capricor Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.